Alere INRatio Recall Articles
February 17, 2017. By Gordon Gibb.
Boston, MA: The INRatio measuring system manufactured by Alere Inc. (Alere) and subject to an Alere recall last year, has oft been highlighted as part of a study focused on the effectiveness of a new-generation blood thinner when compared against warfarin. The oft-made allegation is that inaccurate readings may have given the newer anticoagulant, in this case Xarelto, an unfair advantage over Coumadin (warfarin). The US Food and Drug Administration (FDA) has since opined that in its view, the variances in readings were not drastic enough to sufficiently skew the results.Read [ Alere INRatio Plaintiffs Petition Court to Keep Lawsuit Alive ]
February 7, 2017. By Brenda Craig.
Los Angeles, CA The Alere INRatio home monitoring system offered warfarin (Coumadin) users a convenient way to test their blood clotting rate without having to go the doctor’s office or a laboratory. Instead, they got an expensive, unreliable and potentially dangerous product.Read [ INRatio Class Action Headed for Trial ]
January 21, 2017. By Heidi Turner.
Houston, TX: Patients taking blood thinning medications know they have to be careful to ensure their blood remains in therapeutic levels, to prevent major bleeding episodes. That’s why they use devices like the Alere INRatio2 system, to ensure that if they need it, their blood clots properly. But what happens if they can't be sure the systems that are meant to ensure their safety are actually working properly? That's the issue that was faced by some patients who use the Alere InRatio system, after the system was recalled due to concerns regarding inaccurate results.Read [ Adverse Events for Patients Using Alere INRatio System ]
January 3, 2017. By Gordon Gibb.
Georgetown, DE: An Alere lawsuit filed by former suitor Abbott Laboratories Inc. (Abbott) over a proposed merger is, for the moment, redirecting attention away from the failed INRatio measuring device that was recalled in July. The recalled product nonetheless has a role in the recent performance of Alere Inc. (Alere) that has prompted Abbott to back away. This, in spite of recent assurances from the US Food and Drug Administration (FDA) that any failings of the Alere INRatio device had no bearing on the relationship between warfarin (Coumadin) and Xarelto (rivaroxaban), and the subsequent approval of the latter.Read [ Alere Inc. In Tough over Recalled INRatio, Abbott Merger in Jeopardy ]
December 21, 2016. By Jane Mundy.
Dallas, TX: Negligence allegations against Janssen Pharmaceuticals, Johnson & Johnson and Bayer AG may have fizzled somewhat. Two recent issues do not bode well for plaintiffs filing Alere INRatio lawsuits. The FDA recently announced that the Alere INRatio anti-coagulation monitoring device had no substantial effect on the outcome of the ROCKET-AF trial and in turn did not significantly favor Xarelto as earlier suspected, and a California Alere class action suit in September was dismissed.Read [ Three Points for Alere INRatio Device ]
December 3, 2016. By Gordon Gibb.
Washington, DC: On the heels of a published report in BMJ with regard to the Alere INRatio device, the Alere RecallRead [ FDA Weighs in Alere Recall and Potential for Skewed Results ]
October 6, 2016. By Heidi Turner.
Boston, MA: A new report from BMJ suggests Janssen Pharmaceuticals knew about problems with the Alere INRatio device used during a trial to test a drug's safety but did not inform regulators about those issues. The report, published online September 28, 2016, involves an investigation conducted by The BMJ into whether Janssen and Bayer, co-makers of rivaroxaban, knew about problems with the INRatio device.Read [ Janssen Knew About Issues With Alere INRatio Device ]
September 24, 2016. By Jane Mundy.
Dallas, TX: Now that the blood-testing device called Alere INRatio is known to cause misreadings, attorneys are beginning to focus on blood thinner-related injuries. And there may be legal action against Alere, the manufacturer.Read [ Alere Inaccuracies may lead to Legal Action ]